|
| Status |
Public on Apr 24, 2024 |
| Title |
T.20.C2 |
| Sample type |
RNA |
| |
|
| Source name |
CD3+ selected leukapheresis, patient
|
| Organism |
Homo sapiens |
| Characteristics |
disease state: large B-cell lymphoma
model (1: EXP, 2: poor-EXP): 2
cell type: CD3+ selected leukapheresis, patient
|
| Treatment protocol |
Leukapheresis samples and donor lymphocyte infusions were quickly thawed and CD3+ cells were selected using magnetic anti-CD3 microbeads (Miltenyi Biotec) and the autoMACS Pro Separator (Miltenyi Biotec)
|
| Growth protocol |
n/a
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted from CD3-positive selected cells with miRNeasy Mini kit (Qiagen) and 100 ng of total RNA were used for the transcriptomic analyses
|
| Label |
n/a
|
| Label protocol |
Probe labeling was performed according to Nanostring manufacturer's protocol
|
| |
|
| Hybridization protocol |
Hybridization was performed according to Nanostring manufacturer's protocol, overnight at 65°C, 18h in a thermocycler
|
| Scan protocol |
Cartridges were run on a nCounter Nanostring machine
|
| Data processing |
NanoStringNorm package for R software 4.1.2 (R Foundation for Statistical Computing, Vienna, Austria) was used to generate data and for quality check; the geometric mean of the counts relative to each sample, the mean plus two standard deviations and the total sum of counts options were used to correct the data for technical, background, and batch-effect issues, respectively.
|
| |
|
| Submission date |
Sep 25, 2023 |
| Last update date |
Apr 24, 2024 |
| Contact name |
Luca Agnelli |
| E-mail(s) |
luca.agnelli@istitutotumori.mi.it, luca.agnelli@gmail.com
|
| Phone |
+390223903581
|
| Organization name |
IRCCS Istituto Nazionale dei Tumori
|
| Department |
Department of Advanced Diagnostics
|
| Street address |
Venezian 1
|
| City |
MILAN |
| ZIP/Postal code |
20133 |
| Country |
Italy |
| |
|
| Platform ID |
GPL29417 |
| Series (1) |
| GSE243973 |
Circulating monocyte counts coupled with a 4-gene signature at leukapheresis predict survival of lymphoma patients treated with CAR T |
|
